ORAMED PHARMACEUTICALS WKN: A1CTNU ISIN: US68403P2039 Kürzel: ORMP Forum: Aktien Thema: Hauptdiskussion

Wird von mehreren Analysten mit 23$ bewertet. Sobald die Insulin Pillen die Phase 3 erfolgreich abschließen, dann explodiert hier der Kurs.

https://www.directorstalkinterviews.com/oramed-pharmaceuticals-inc.---consensus-indicates-potential-186.4-upside/412975261

https://tntribune.com/indian-firms-try-to-make-non-invasive-covid-19-vaccinations-mainstream/

Ich kann dir nicht mehr genau sagen, wo ich das gelesen habe, aber meines Wissens sind sie in die Phase 1 eingestiegen. Wichtig ist, das Oramed da bißchen Gas gibt. Die anderen Unternehmen werden sich das genau anschauen und versuchen ein konkurierendes Produkt auf den Markt zu bringen. Ist genau wie mit den MRNA Impfstoffen. Früher wurde Bointech und Co. belächelt und jetzt sollen sie die Welt retten. Ich drücke uns allen fest die Daumen, das Oramed mit seinem Vorhaben voran kommt und evtl. von größeren Unternehmen eine Unterstützung bekommt.

Pfizer plant meines Wissens ein Covidmedikament zur Heilung und Oramed ein Impfstoff zum schlucken.

Danke für die Infos nionus. Jetzt muss nur noch die nächste Testphase losgehen, sonst ist der Vorsprung anderen Unternehmen wie Pfizer weg.

und nochmal ein Beitrag zur Covid-Pille: https://tntribune.com/indian-firms-try-to-make-non-invasive-covid-19-vaccinations-mainstream/

🚀💥

https://www.pharmazeutische-zeitung.de/schluckimpfung-gegen-covid-19-124575/

⬆️⬆️⬆️ein Interview mit dem CEO zu der covid-Pille... scheint wohl gerade Im Urlaub zu sein😎

https://youtu.be/ThKXjq7pJTY

Wenn sich der Artikel bewahrheitet, dann wäre das ein Befreiungsschlag für die Menschen und uns Aktionäre !!!

Zulassung der covid-Pille binnen 6 Monaten! Wäre fast zu schön um wahr zu sein: https://www.israel21c.org/oral-covid-vaccine-candidate-produces-antibodies-in-pigs/

https://stockinvest.us/stock/ORMP

https://www.mdr.de/brisant/schluckimpfung-corona-100.html

Teil2: Overcoming Vaccine Hesitancy It is also possible that a vaccine in pill form will help some people overcome vaccine hesitancy, or the fear of taking a relatively new vaccine. According to NCBI, vaccine hesitancy stems from a number of factors, including the lack of trust in public health agencies. Some people who are concerned about accepting a vaccine injection might be more willing to get a COVID-19 vaccine in oral pill format. Oravax expects to begin clinical trials in 2Q 2021. The several positive takeaways from this development include that Oramed has expanded its potential addressable commercial market into COVID-19 and potentially other viruses and has also shown the potential versatility of the technology behind its oral delivery platform. Other biotech companies such as Vaxart (NASDAQ: VXRT), are also researching and/or developing vaccines, including in oral format, as well as nasal sprays (Altimmune [NASDAQ: ALT]) and precision transdermal (TDS) patch formats. However, there is still a tremendous global need for COVID-19 vaccines. Given the relatively early stage of inoculations at this point, we believe there is ample demand for vaccines and Oravax will be able to enjoy early mover advantage. Moreover, many in the medical community believe that a COVID-19 vaccine is likely to be recommended annually just as the flu vaccine is, which further underscores the need for a greater number of vaccine manufacturers. Separately, Pfizer (NYSE: PFE) has indicated that it is pursuing early stage oral studies for a drug to treat the COVID-19 disease, not to inoculate against it. Advancing Multiple Clinical Studies in 2021 The Oravax vaccine represents a successful expansion of Oramed’s POD™ oral protein delivery platform into the vaccine development market, as noted. Simultaneously, Oramed continues to pursue opportunities in its core diabetes space, as well. In 2021, in addition to focusing on moving the COVID-19 vaccine forward through Oravax, Oramed also continues to advance its Oral Insulin in dual concurrent Phase 3 studies. The company recently announced that it has enrolled and randomized 25% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of ORMD-0801, its oral insulin capsule to treat type 2 diabetes (T2D). Oramed has also screened the first patients in its ORA-D-013-2 study, the second of the two above-noted concurrent Phase 3 studies of ORMD-0801 for the treatment of T2D. The ORA-D-013-2 study is planned to enroll 450 T2D patients. This dual study represents the world’s first pivotal Phase 3 oral insulin trial conducted through an FDA approved protocol. Oramed also remains focused on advancing its NASH study and has also screened the first patients in this global trial. The company also is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901 for the treatment of diabetes. SUBSCRIBE TO ZACKS SMALL CAP RESEARCH